



Attorney Docket No. 59573(46865)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Anne Marie HEEGAARD, et al.

U.S.S.N.: 10/623,150

EXAMINER: Not yet assigned

FILED: July 18, 2003

GROUP: 1632

FOR: METHOD FOR SCREENING COMPOUNDS FOR ACTIVITY IN TREATING
AN OSTEOCLAST RELATED BONE DISEASE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the:
Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on
February 11, 2004.

By Patricia A. Barnes
Patricia A. Barnes

COMMISSIONER FOR PATENTS
P. O. BOX 1450
ALEXANDRIA, VA 22313-1450

Date: February 11, 2004

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications or other information submitted for consideration by the Office are listed on PTO-1449, attached hereto.

II. COPIES

- a. X Submitted herewith is a legible copy of (i) each U.S and foreign patent; (ii) each publication or that portion which caused it to be listed; and (iii) all other information or that portion which caused it to be listed.
- b. This application relies, under 35 U.S.C. § 120, on the earlier filing date of prior application Serial No. , filed on . The following references were submitted to, and/or cited by, the Office in the prior application (s) and, therefore, are not required to be provided in this application.

III. CONCISE EXPLANATION OF THE RELEVANCE
(check at least one box)

- a. X Except as may be indicated below in (b), all of the patents, publications or other information are in the English language or were cited in an English language Search Report, a copy of which is attached hereto (concise explanation not required).
- b. A concise explanation of the relevance of all patents, publications or other information listed that is not in the English language is as follows:
- c. The following additional information is provided for the Examiner's consideration:

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(b)
(check one box)

- a. within three months of the filing date of a national application (37 C.F.R. § 1.97(b) (1). No fee or certification is required.
- b. within three months of the date of entry of the national stage as set forth in §1.491 in an international application (37 C.F.R. § 1.97(b) (2). No fee or certification is required.

b. _____ no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

- c. _____ Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned certifies that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby certifies that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

_____ Please charge Deposit Account No. 04-1105 in the amount of \$180.00 for the above-indicated fee. A triplicate copy of this paper is attached.

 X No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule, with a petition if necessary, and charge the appropriate fee to Deposit Account No. **04-1105**.

Respectfully submitted,

Date: 11 Feb 2004



Robert L. Buchanan
Reg. No. 40,927
Attorney for Applicant(s)

EDWARDS & ANGELL, LLP
P. O. Box 55874
Boston, MA 02205
Tel: (617) 439-4444
Fax: (617) 439-4170 / 7748
Customer No.: 21874
#433203

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

DOCKET NO:

59573 (46865)

SERIAL NO.:

10/623,150

APPLICANT(S): Anne Marie HEEGAARD, et al.

FILING DATE:

July 18, 2003

GROUP NO.:

1632

UNITED STATES PATENT DOCUMENTS

EXAM. INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
BA	WO 00/24707	04/05/00	PCT			
BB	WO 99/16909	08/04/99	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

CA	Siike Brandt, Thomas J. Jentsch; CIC-6 and CIC-7 are two novel broadly expressed members of the CLC chloride channel family; Center for Molecular Neurobiology Hamburg (ZMNH), FEBS Letters 377 (1995) 15-20					
CB	Uwe Kornak, et al.; Complete genomic structure of the CLCN6 and CLCN7 putative chloride channel genes; Biochimica et Biophysica Acta 1447 (1999) 100-106					
CC	Erna Cleiren, et al.; Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the CLCN7 chloride channel gene; Human Molecular Genetics, 2001, Vol. 10, No. 25 2681-2867					
CD	Shinichi Uchida, et al.; Cloning and Expression of a PKC-Regulated Chloride Channel; Japanese Journal of Physiology, 44, Suppl. 2, S55-S62, 1994					
CE	Paul H. Schlesinger, et al.; Characterization of the Osteoclast Ruffled Border Chloride Channel and Its Role in Bone Resorption; The Journal of Biological Chemistry Vol. 272, No. 30, Issue of July 25, pp 18636-18643, 1997					
CF	S.H.S. Pearce; Straightening out the renal tubule: advances in the molecular basis of the inherited tubulopathies; Q.J. Med 1998; 91:5-12					
CG	Dayue Duan, et al.; Molecular identification of a volume-regulated chloride channel; Nature/Vol 390/27 November 1997					
CH	Uwe Kornak, et al.; Loss of the CIC-7 Chloride Channel Leads to Osteopetrosis in Mice and Man; Cell, Vol. 104, 205-215, January 26, 2001, Copyright ©2001 by Cell Press, pp. 205-215					
CI	Sandra M. Stobrawa, et al.; Disruption of CIC-3, a Chloride Channel Expressed on Synaptic Vesicles, Leads to a Loss of the Hippocampus; Neuron, Vol 29, 185-196, January, 2001, Copyright ©2001 by Cell Press, pp. 185-196					
CJ	Nils Piwon, et al.; CIC-5 Cl ⁻ channel disruption impairs endocytosis in a mouse model for Dent's disease; Nature Vol 408/16 November 2000, pp. 369-373					
CK	David Clapham; How to Lose Your Hippocampus by Working on Chloride Channels; Neuron, Vol. 29, 1-6, January, 2001, Copyright ©2001 by Cell Press, pp. 1-3					

EXAMINER:

DATE: